# US 2021/0340496 A1 · Compositions and methods for modifying regulatory t cells

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0340496 A1
- Document ID: US20210340496A1
- Status: Published application
- Kind: A1
- Application number: 17/284,396
- Filed: 2019-10-10
- Published: 2021-11-04
- Earliest claimed: 2018-10-10
- Assignees: The Regents of the University of California
- Applicants: The Regents of the University of California
- Inventors: Alexander Marson; Jessica T. Cortez; Jeffrey A. Bluestone; Eric Shifrut; Frederic Van Gool
- Web page: https://patentgrep.com/patent/US20210340496A1

## CPC

- C12N 9/22: Ribonucleases {[RNase]; Deoxyribonucleases [DNase]}
- C12N 15/11: DNA or RNA fragments; Modified forms thereof (DNA or RNA not used in recombinant technology, C07H21/00); {Non-coding nucleic acids having a biological activity}
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/22: Immunosuppressive or immunotolerising
- A61K 40/416: {Antigens related to auto-immune diseases; Preparations to induce self-tolerance}
- A61K 40/42: Cancer antigens
- A61P 35/00: Antineoplastic agents
- C12N 5/0637: {Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg}
- C12N 9/226: {Class 2 CAS enzyme complex, e.g. single CAS protein}
- C12N 15/907: {in mammalian cells}
- C12N 2310/20: involving clustered regularly interspaced short palindromic repeats [CRISPR]
- C12N 2800/80: Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Provided herein are compositions and methods for modifying regulatory T cells. The inventors have identified nuclear factors that influence expression of Foxp3, a key transcriptional regulator of Treg cells. Treg cells can be modified by inhibiting and/or overexpressing one or more of these nuclear factors to produce stabilized Treg cells or destabilized Treg cells.

## Claims

### Claim 1

A method of increasing human regulatory T (Treg) cell stability, the method comprising:
inhibiting expression of one or more nuclear factors set forth in Table 1 and/or overexpressing one or more nuclear factors set forth in Table 2, in the human Treg cell.

### Claim 2

A method of decreasing human Treg cell stability, the method comprising: inhibiting expression of a one or more nuclear factors set forth in Table 2 and/or overexpressing one or more nuclear factors set forth in Table 1, in the humanTreg cell.

### Claim 3 (depends on 1)

The method of claim 1, wherein the inhibiting comprises reducing expression of the nuclear factor, or reducing expression of a polynucleotide encoding the nuclear factor.

### Claim 4 (depends on 1)

The method of claim 1, wherein the overexpressing comprises increasing expression of the nuclear factor, or increasing expression of a polynucleotide encoding the nuclear factor.

### Claim 5 (depends on 4)

The method of claim 4, wherein the overexpressing comprises introducing a polynucleotide encoding the nuclear factor into the Treg cell.

### Claim 6 (depends on 3)

The method of claim 3, wherein the inhibiting comprises contacting a polynucleotide encoding the nuclear factor with a targeted nuclease, a guide RNA (gRNA), an siRNA, an antisense RNA, microRNA (miRNA), or short hairpin RNA (shRNA).

### Claim 7 (depends on 6)

The method of claim 6, wherein the inhibiting comprises contacting the polynucleotide encoding the nuclear factor with at least one gRNA and optionally a targeted nuclease, wherein the at least one gRNA comprises a sequence selected from Table 3.

### Claim 8 (depends on 1)

The method of claim 1, wherein the inhibiting comprises mutating the polynucleotide encoding the nuclear factor.

### Claim 9 (depends on 8)

The method of claim 8, wherein the inhibiting comprises contacting the polynucleotide with a targeted nuclease.

### Claim 10 (depends on 9)

The method of claim 9, wherein the targeted nuclease introduces a double-stranded break in a target region in the polynucleotide.

### Claim 11 (depends on 6)

The method of claim 6, wherein the targeted nuclease is an RNA-guided nuclease.

### Claim 12 (depends on 11)

The method of claim 11, wherein the RNA-guided nuclease is a Cpf1 nuclease or a Cas9 nuclease and the method further comprises introducing into a Treg cell a gRNA that specifically hybridizes to a target region in the polynucleotide.

### Claim 13 (depends on 12)

The method of claim 12, wherein the Cpf1 nuclease or the Cas9 nuclease and the gRNA are introduced into the Treg cell as a ribonucleoprotein (RNP) complex.

### Claim 14 (depends on 9)

The method of claim 9, wherein the inhibiting comprises performing clustered regularly interspaced short palindromic repeats (CRISPR)/Cas genome editing.

### Claim 15 (depends on 1)

The method of claim 1, wherein the Treg cell is administered to a human following the inhibiting and/or the overexpressing.

### Claim 16 (depends on 1)

The method of claim 1, wherein the Treg cell is obtained from a human prior to treating the Treg cell to inhibit expression of the nuclear factor and/or overexpress the nuclear factor, and the treated Treg cell is reintroduced into a human.

### Claim 17 (depends on 16)

The method of claim 16, wherein inhibiting expression and/or overexpression results in a Treg cell having increased stability.

### Claim 18 (depends on 17)

The method of claim 17, wherein the human has an autoimmune disorder.

### Claim 19 (depends on 16)

The method of claim 16, wherein inhibiting expression and/or overexpression results in a Treg cell having decreased stability.

### Claim 20 (depends on 19)

The method of claim 19, wherein the human has cancer.

### Claim 21 (depends on 1)

A Treg cell made by the method of claim 1.

### Claim 22

A Treg cell comprising:
(a) a genetic modification or heterologous polynucleotide that inhibits expression of a nuclear factor set forth in Table 1 and/or a heterologous polynucleotide that encodes a nuclear factor set forth in Table 2;
(b) a genetic modification or heterologous polynucleotide that inhibits expression of a nuclear factor set forth in Table 2 and/or a heterologous polynucleotide that encodes a nuclear factor set forth in Table 1; or
(c) at least one guide RNA (gRNA) comprising a sequence selected from Table 3.

### Claim 23

(canceled)

### Claim 24

(canceled)

### Claim 25 (depends on 22)

The Treg cell of claim 22, wherein the expression of a nuclear factor set forth in Table 1 or Table 2 is reduced in the Treg cell relative to the expression of the nuclear factor in a Treg cell not comprising a gRNA.

### Claim 26

A method of destabilizing Tregs in a subject in need thereof, comprising inhibiting expression of a one or more nuclear factors set forth in Table 2 and/or overexpressing one or more nuclear factors set forth in Table 1, in the humanTreg cells of the subject.

### Claim 27 (depends on 26)

The method of claim 26, wherein inhibiting expression of a one or more nuclear factors set forth in Table 2 and/or overexpressing one or more nuclear factors set forth in Table 1 occurs in vivo.

### Claim 28 (depends on 26)

The method of claim 26, wherein the method of destabilizing the Treg cells comprises:
a) obtaining Treg cells from the subject;
b) destabilizing the Treg cells by inhibiting expression of a nuclear factor set forth in Table 2 and/or overexpressing a nuclear factor set forth in Table 1 in the Treg cells; and
c) administering the destabilized Treg cells to the subject.

### Claim 29 (depends on 26)

The method of claim 26, wherein the subject has cancer.

### Claim 30

A method of stabilizing Tregs in a subject in need thereof, comprising inhibiting expression of a one or more nuclear factors set forth in Table 1 and/or overexpressing one or more nuclear factors set forth in Table 2, in the humanTreg cells of the subject.

### Claim 31 (depends on 30)

The method of claim 30, wherein inhibiting expression of a one or more nuclear factors set forth in Table 1 and/or overexpressing one or more nuclear factors set forth in Table 2 occurs in vivo.

### Claim 32 (depends on 30)

The method of claim 30, wherein the method of stabilizing the Treg cells comprises:
a) obtaining Treg cells from the subject;
b) stabilizing the Treg cells by inhibiting expression of a nuclear factor set forth in Table 1 and/or overexpressing a nuclear factor set forth in Table 2 in the Treg cells; and
c) administering the destabilized Treg cells to the subject.

### Claim 33 (depends on 30)

The method of claim 30, wherein the subject has an autoimmune disorder.

### Claim 34 (depends on 22)

A method of treating an autoimmune disorder in a subject, the method comprising administering a population of the Treg cells of claim 22 to a subject that has an autoimmune disease.

### Claim 35 (depends on 23)

A method of treating cancer in a subject, the method comprising administering a population of the Treg cells of claim 23 to a subject that has cancer.
